Neurocrine Biosciences (NBIX) EBIT Growth (3y) (2013 - 2026)
Powered by 
Analysis
Neurocrine Biosciences (NBIX) EBIT Growth (3y) (2013 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 643.26 Bn | 622.50 Bn | 17.26 Bn | 7.09% |
| 2 | AbbVie | 443.31 Bn | 436.74 Bn | 12.70 Bn | 12.54% |
| 3 | Merck | 364.74 Bn | 357.60 Bn | 12.21 Bn | 51.64% |
| 4 | Novartis Ag | 266.46 Bn | 258.77 Bn | 11.24 Bn | 19.17% |
| 5 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | 7.73% |
| 6 | Sanofi | 52.33 Bn | 44.95 Bn | 10.79 Bn | -15.60% |
| 7 | Revolution Medicines | 43.79 Bn | 43.79 Bn | - | - |
| 8 | Incyte | 25.23 Bn | 20.69 Bn | 1.57 Bn | 53.28% |
| 9 | United Therapeutics | 21.67 Bn | 19.01 Bn | 683.80 Mn | 1.82% |
| 10 | Neurocrine Biosciences | 15.65 Bn | 15.26 Bn | 935.80 Mn | 27.21% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 27.21% |
| Mar 31, 2026 | 54.58% |
| Dec 31, 2025 | 26.82% |
| Sep 30, 2025 | 39.63% |
| Jun 30, 2025 | 38.59% |
| Mar 31, 2025 | 96.72% |
| Dec 31, 2024 | 80.82% |
| Sep 30, 2024 | 60.45% |
| Jun 30, 2024 | 32.29% |
| Mar 31, 2024 | 46.63% |
| Dec 31, 2023 | 27.92% |
| Sep 30, 2023 | 73.11% |
| Jun 30, 2023 | -1.32% |
| Mar 31, 2023 | -57.93% |
| Dec 31, 2022 | 28.44% |
| Sep 30, 2022 | -0.86% |
| Jun 30, 2022 | 16.72% |
| Mar 31, 2022 | 26.63% |
| Dec 31, 2021 | -54.21% |
| Sep 30, 2021 | -6.43% |